Cathryn Campbell was quoted in the November 2004 issue of California Lawyer in regard to the success of the biotech industry, now exceeding $39 billion and the success is due in large part to the amount of litigation. Cathryn Campbell states, "[V]irtually every product that's come out of biotech has been the subject of a lawsuit." "Those lawsuits have included everything from infringement to inventorship to licensing to whether royalties have been sufficient." Cathryn Campbell explains how much of the litigation stems from the early licensing agreements and how the royalty base is effected. She concludes that "[E]ven though we're getting more sophisticated, there will be a lot of disputes, because of the amount of money at stake and the difficulty of writing prospective licenses...."